Edition:
United States

Cipla Ltd (CIPL.BO)

CIPL.BO on Bombay Stock Exchange

573.50INR
5:59am EDT
Change (% chg)

Rs3.45 (+0.61%)
Prev Close
Rs570.05
Open
Rs570.00
Day's High
Rs574.85
Day's Low
Rs564.55
Volume
56,348
Avg. Vol
140,773
52-wk High
Rs621.90
52-wk Low
Rs479.00

Select another date:

Fri, Aug 11 2017

UPDATE 1-India's Cipla Q1 profit rises 20 pct, beats estimates

* South Africa revenue up 21 pct (Adds details from press release)

India's Cipla June-qtr profit rises 20 pct, beats estimates

Aug 11 Cipla Ltd, India's fourth-largest drugmaker by sales, reported a 20 percent rise in quarterly profit, beating analysts' estimates.

BRIEF-India's Cipla June-qtr consol profit up about 21 pct

* June quarter consol net profit 4.09 billion rupees versus 3.39 billion rupees last year

BRIEF-India's Cipla launches rectal artesunate suppositories for severe malaria in young children

* Launches quality-assured rectal artesunate suppositories for severe malaria in young children

BRIEF-Dr.Reddy's Labs recalls Cipla-made zenatane capsule from U.S. markets

* Dr.Reddy's Laboratories clarifies on news item, "Dr Reddy's recalls 3.25l cartons Cipla-made acne drug from US".

India's Cipla lowers bio drugs investment, sharpens focus on respiratory

MUMBAI Cipla Ltd , India's fifth-largest drugmaker by sales, plans to reduce investment in biosimilars to sharpen its focus on building a portfolio of high-margin respiratory products, the company's chief executive said on Thursday.

UPDATE 1-India's Cipla lowers bio drugs investment, sharpens focus on respiratory

* Posts Q4 loss vs. analysts' forecast for profit (Recasts with CEO's comments)

Indian drugmaker Cipla narrows loss in Jan-March, misses forecasts

MUMBAI, May 25 Cipla Ltd, India's fifth-largest drugmaker by sales, reported a smaller quarterly loss for January-March, but missed expectations of a profit for the period.

BRIEF-India's Cipla March-qtr loss narrows

* Consol march quarter total income from operations 35.82 billion rupees

BRIEF-Cipla U.S. arm signs worldwide licensing deal with MEDRx

* Medrx is eligible to receive up to USD 30 million cumulatively through upfront and developmental, regulatory, and commercial milestones payments

Select another date: